[Short-and long-term effects of cannabinoids on memory, cognition and mental illness].
Marijuana is considered the most commonly used drug in the world, with estimated millions of users. There is dissent in the medical world about the positive and negative effects of marijuana, and recently, a large research effort has been directed to that domain. The main influencing drug ingredient is THC, which acts on the cannabinoid system and binds to the CB1 receptor. The discovery of the receptor led to the finding of an endogenous ligand, anandamide, and another receptor-CB2. The researchers also discovered that cannabinoids have extensive biological activity, and its short and long-term effects may cause cognitive and emotional deficiencies. Findings show that the short-term effects, such as shortterm memory and verbal Learning, are reversible. However, despite the accumulation of evidence about long-term cognitive damage due to cannabis use, it is difficult to find unequivocal results, arising from the existence of many variables such as large differences between cannabis users, frequency of use, dosage and endogenous brain compensation. Apart from cognitive damage, current studies investigate how marijuana affects mental illness: a high correlation between cannabis use and schizophrenia was found and a high risk to undergo a psychotic attack. Furthermore, patients with schizophrenia who used cannabis showed a selective neuro-psychological disruption, and similar cognitive deficiencies and brain morphological changes were found among healthy cannabis users and schizophrenia patients. In contrast to the negative effects of marijuana including addiction, there are the medical uses: reducing pain, anxiety and nausea, increasing appetite and an anti-inflammatory activity. Medicalization of marijuana encourages frequent use, which may elevate depression.
MoLecular Medicine Laboratory, Technion-Israel Institute of Technology, Haifa, Israel. shirasagie@gmail.com
Shira
S
Sagie
Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
Yehuda
Y
Eliasi
Cancer and Vascular Biology Research Center, Technion-Israel Institute of Technology, Haifa, Israel.
Ido
I
Livneh
Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
Yosi
Y
Bart
Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel.
Einat
E
Monovich
D001095:Arachidonic Acids / Q000378:metabolism; D063386:Cannabinoid Receptor Agonists / Q000009:adverse effects* / Q000494:pharmacology; D002186:Cannabinoids / Q000009:adverse effects* / Q000494:pharmacology; D003071:Cognition / Q000187:drug effects*; D013759:Dronabinol / Q000009:adverse effects / Q000494:pharmacology; D063388:Endocannabinoids / Q000378:metabolism; D006801:Humans; D008568:Memory / Q000187:drug effects; D001523:Mental Disorders / Q000139:chemically induced; D053284:Polyunsaturated Alkamides / Q000378:metabolism; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors
D001095:Arachidonic Acids; D063386:Cannabinoid Receptor Agonists; D002186:Cannabinoids; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D013759:Dronabinol; C078814:anandamide